Sustained-release drug carrier composition
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
1. Tricalcium phosphate (TCP) particles having their surface coated fully or partially with a biocompatible matrix composition, the matrix composition comprising:
a. a biodegradable polymer;
b. a first lipid comprising a sterol;
c. a second lipid comprising at least one phospholipid having hydrocarbon chains of at least 14 carbons; and
d. a pharmaceutical active agent;
wherein the matrix composition: (i) is lipid saturated, (ii) has a multilayered structural in which the biodegradable polymer and lipids are ordered in the form of layers and (iii) when maintained in an aqueous environment provides sustained release of the pharmaceutical active agent.
2. The coated particles of claim 1 , wherein said phospholipid is a phosphatidylcholine having fatty acid moieties having at least 14 carbons.
3. The coated particles of claim 1 wherein the biodegradable polymer is a biodegradable polyester selected from the group consisting of PLA (polylactic acid), PGA (poly glycolic acid) and PLGA (Poly (lactic co glycolic acid).
4. The coated particles of claim 1 wherein the pharmaceutical active agent is selected from an antibiotic, an antifungal, a non-steroidal anti-inflammatory drug, a steroid, an anti-cancer agent, an osteogenic factor and a bone resorption inhibitor.
5. The coated particles of claim 4 , wherein said pharmaceutical active agent is an antibiotic or antifungal.
6. The coated particles of claim 5 , wherein the antibiotic is selected from the group consisting of doxycycline and doxycycline hyclate.
7. The coated particles of claim 4 , wherein said pharmaceutical active agent is an anticancer agent.
8. The coated particles of claim 7 , wherein the anticancer agent is docetaxel.
9. The coated particles of claim 4 , wherein said pharmaceutical active agent is a non-steroidal anti-inflammatory drug (NSAID).
10. The coated particles of claim 4 , wherein said pharmaceutical active agent is a steroid.
11. The coated particles of claim 10 , wherein said steroid is dexamethasone or dexamethasone 21-phosphate.
12. The coated particles of claim 4 , wherein said pharmaceutical active agent is selected from an osteogenic factor or a bone resorption inhibitor.
13. The coated particles of claim 1 , wherein the weight ratio of total lipids to said biodegradable polymer is between 1.5:1 and 9:1 inclusive.
14. The coated particles of claim 1 , comprising a plurality of pharmaceutical active agents selected from an antibiotic, an antifungal, a non-steroidal anti-inflammatory drug (NSAID), a steroid, an anti-cancer agent, an osteogenic factor and a bone resorption inhibitor.
15. The coated particles of claim 1 , wherein said matrix composition is homogeneous.
16. The coated particles of claim 1 , wherein the matrix composition further comprises an additional lipid selected from the group consisting of: a sphingolipid, a tocopherol, an additional phospholipid selected from the group consisting of a phosphatidylserine, a phosphatidylglycerol, and a phosphatidylinositol, a free fatty acid having 14 or more carbon atoms, a PEGylated lipid and any combination thereof.
17. The coated particles of claim 1 , wherein the matrix composition further comprises a targeting moiety capable of interacting with a target molecule selected from the group consisting of a collagen molecule, a fibrin molecule and a heparin.
18. The coated particles of claim 1 , wherein said sterol is a cholesterol.
19. The coated particles of claim 18 , wherein said cholesterol is present in an amount of 10-50 percent of the total weight of the lipid content of said matrix composition.
20. The coated particles of claim 1 , wherein the at least one phospholipid is selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and any combination thereof.
21. A pharmaceutical composition comprising the coated particles of claim 1 , for sustained release of the pharmaceutically active agent.